Are you a journalist?

Learn to know ALK

If you have any queries please feel free to contact Media Relations at ALK headquarters or one of our global offices.

The press releases in this press room contains information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.

News

See all
  • Post date
    06/15/2026
    EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis
    Read more
  • Post date
    06/11/2026
    Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
    Read more
  • Post date
    06/04/2026
    ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
    Read more
  • Post date
    06/01/2026
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
    Read more
  • Post date
    05/29/2026
    ALK to present at the Jefferies Global Healthcare Conference in New York
    Read more
  • Post date
    05/04/2026
    ALK upgrades its full-year outlook
    Read more
  • Post date
    05/04/2026
    Three-month interim report (Q1) 2026 (unaudited)
    Read more
  • Post date
    04/28/2026
    Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026
    Read more
  • Post date
    04/20/2026
    ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
    Read more

Media Relations

Per Plotnikof
Vice President,
Corporate Communications,
Investor Relations and Strategic Planning
Phone: +45 22612525
Email: PPIDK@alk.net

Jeppe Ilkjær
Media Relations Manager
Corporate Communications
Phone: +45 30502014
Email: Jeppe.Ilkjaer@alk.net

About ALK
Read more about the profile of ALK, the market leader in allergy immunotherapy
Key financial figures
Read more about ALK’s latest financial results
Journalists are always welcome to contact ALK’s Media Relations team.

Images

Find a wide selection of images available for download for the press
Steen Riisgaard, CEO
Download image
Production facilities, Hørsholm
Download image
alk_produktion6_0
Production facilities, Hørsholm
Download image
alk_produktion3_1
Production facilities, Hørsholm
Download image
alk_produktion5
Production facilities, Hørsholm
Download image
Family_website_0
ALK HQ, Hørsholm
Download image
Last updated: 2016.11.14